- Design
- Phase 3 randomised trial at 4 high-volume European centres
- Population
- 202 patients with resectable oesophageal or junctional adenocarcinoma
- Primary outcome
- Number of resected lymph nodes
- Effect
- Median 36 vs 32 nodes (P = .005); similar complications and 1-year survival
This phase 3 trial, published in September, randomised patients with resectable adenocarcinoma of the oesophagus or oesophagogastric junction at four high-volume European centres to robot-assisted minimally invasive oesophagectomy (RAMIE) or conventional minimally invasive oesophagectomy (MIE). Of 218 randomised, 202 had transthoracic resection; nine in ten were men.
The primary endpoint, lymph node yield, favoured RAMIE: median 36 vs 32 nodes (P = .005). Luminal R0 resection was 99.0% vs 97.0%. Complication rates were similar, 90-day mortality was 1.0% vs 3.0% (not significant), and 1-year survival did not differ.
Node yield is a surrogate. A larger lymphadenectomy is expected to help staging and perhaps survival, but this trial has not yet shown a survival difference, and five-year follow-up is planned.
For units deciding on robotic platforms, this supports RAMIE as at least as safe as MIE in experienced hands. It does not show that patients live longer, and results from high-volume centres may not transfer to units early in their learning curve.
- RAMIE yielded a median of 36 nodes against 32 with conventional MIE.
- Complications, 90-day mortality and 1-year survival were similar between approaches.
- All four centres were high-volume; expect a learning curve elsewhere.
- Node yield is a staging surrogate — survival benefit is not yet shown.
- Audit your own node yield and R0 rate before and after adopting a robotic platform.
Why it matters
It is randomised evidence for the claim that the robot buys a more thorough lymphadenectomy, which until now rested mostly on series.
Don't overread it
Lymph node count is a surrogate; this trial has not shown that RAMIE improves survival.
The statistics, in plain English
A median difference of four nodes is statistically clear (P = .005). Whether four extra nodes change outcomes is not answered here. The 90-day mortality difference (1% vs 3%) is based on a handful of deaths and is compatible with chance.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for general surgery, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free